Johnson & Johnson and Actelion end discussion about strategic transaction
Johnson & Johnson confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. regarding a potential transaction. Johnson & Johnson was not able to reach an agreement that it believed would create adequate value for its shareholders.
Actelion has taken note of the announcement by Johnson & Johnson (J&J) and confirms that J&J has withdrawn from the discussions. Actelion is engaged in discussions with another party regarding a possible strategic transaction.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Sympatec GmbH - Clausthal-Zellerfeld, Germany
Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator - Novel Approach Has Potential for Treatment of Multiple CNS Disorders
Researchers Discover Gene that Contributes to Sense of Balance

Airy cellulose from a 3D printer - A lot of potential applications in medicine
James_W._Black
Breast implants could become safer thanks to cell-friendly surface
